Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 21, Issue 11, Pages 1743-1750Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.2012.724398
Keywords
amyloid; fibrosis; IAPP; imatinib mesylate; insulin; pancreatic beta-cells; Type-2 diabetes
Categories
Ask authors/readers for more resources
Introduction: The small tyrosine kinase inhibitor Imatinib Mesylate (Gleevec) protects against diabetes, but it is not known how. Areas covered: It has been suggested that islet amyloid and fibrotic deposits promote beta-cell failure and death, leading to Type-2 diabetes. As Imatinib is known to possess anti-fibrotic/amyloid properties, in for example systemic sclerosis and mouse models for Alzheimer's disease, the present review will discuss the possibility that Imatinib acts, at least in part, by ameliorating islet hyalinization and its consequences in the pathogenesis of Type-2 diabetes. Expert opinion: A better understanding of how Imatinib counteracts Type-2 diabetes will possibly help to clarify the pathogenic role of islet amyloid and fibrosis, and hopefully lead to improved treatment of the disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available